Applications of 16A,17A-Epoxyprogesterone in Industrial Manufacturing

With decades of experience as a dedicated manufacturer of steroidal chemical raw materials, we serve specialized downstream partners that depend on 16A,17A-Epoxyprogesterone for advanced synthesis in regulated sectors. Our team collaborates closely with leading pharmaceutical and veterinary laboratories, as well as intermediates synthesis plants, optimizing the integration of this advanced intermediate to consistently meet stringent industry, regional, and customer-driven specifications. Below we outline authentic applications supported by our technical documentation and end-user validation, focusing on real-world differentiated scenarios.

1. Corticosteroid API Synthesis

Industrial-scale corticosteroid manufacturers regularly include 16A,17A-Epoxyprogesterone as a key intermediate in the multi-step chemical synthesis of active pharmaceutical ingredients (APIs), such as dexamethasone and betamethasone. This material enters after core structure modification, feeding into oxidation, reduction, and esterification sequences in regulated cGMP environments. The precise addition ratio and quality directly impact the yield and purity requirements set by major health authorities.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) Monographs for steroid hormones
• United States Pharmacopeia (USP) API monographs
• China GMP for APIs (2020 revision)

Typical usage ratio

• Dosage in reaction batch varies from 8% to 16% w/w of substrate input, adjusted according to specific process stoichiometry and reaction scale.

Downstream process integration

• Fed into chemical reactors following initial ring structure preparation, prior to chlorination or hydroxylation steps in corticosteroid synthesis lines.

Final product types

• Pharmaceutical-grade corticosteroid active ingredients including dexamethasone acetate and betamethasone sodium phosphate.

2. Veterinary Steroidal Drug Intermediates

Veterinary pharmaceutical manufacturers introduce 16A,17A-Epoxyprogesterone as a critical raw material to develop progesterone derivatives for livestock reproductive management medications and anti-inflammatory products. The raw material gets integrated in multi-step synthetic routes overseen by veterinary cGMP controls to ensure traceability and veterinary safety compliance.

Industry compliance standards

• VICH GLs (Veterinary International Cooperation on Harmonisation) for APIs
• Chinese Veterinary Pharmacopoeia (2020 edition)
• EU Regulation (EU) 2019/6 on veterinary medicinal products
• ISO 9001:2015 for chemical quality management systems

Typical usage ratio

• Blended at 7–12% weight of starting material input, depending on final drug molecule type and local veterinary regulation limits.

Downstream process integration

• Charged into closed reactor vessels for stepwise addition post-initial ring expansion, where it undergoes catalytic or enzymatic transformation to progesterone-based veterinary APIs.

Final product types

• Injectable veterinary suspensions (e.g., progestogen-based estrus synchronization drugs)
• Veterinary anti-inflammatory formulations for bovines and swine

3. Intermediate for Fertility Regulation APIs

Human reproductive health product manufacturers purchase this intermediate for the targeted synthesis of hormone APIs used in ovulation induction and contraception medicines. Its structure allows for high selectivity in subsequent hydrogenation and acetylation processes in specialized pharmaceutical facilities that follow strict batch production recordkeeping and impurity profile monitoring.

Industry compliance standards

• Good Manufacturing Practice (EU GMP Part II) for intermediates
• U.S. Drug Enforcement Administration (DEA) List I chemical regulations, if applicable
• WHO Model List of Essential Medicines requirements for reproductive APIs
• ICH Q3A/B: Impurities in new drug substances/intermediates

Typical usage ratio

• Typical process feeds 6%–14% by mass, optimized through pilot trials for final yield and impurity minimization.

Downstream process integration

• Incorporated after enone activation sequences into multi-stage synthesis trains for high-purity gestagenic hormone APIs production.

Final product types

• Oral hormonal contraceptive APIs (e.g., norgestimate)
• Gonadotropin preparation raw materials

4. Synthesis of Steroid Analysis Standards

Analytical reference material producers source this chemical to prepare certified reference standards for steroid detection and quantification methods. It is precisely weighed and integrated in the synthesis of calibration materials, fulfilling regulatory requirements for purity, identity, and stability for global QC laboratories and pharmaceutical control applications.

Industry compliance standards

• ISO 17034:2016 (General requirements for reference material producers)
• ISO/IEC 17025:2017 (Testing and calibration laboratories)
• National Metrology Institute requirements
• USP Reference Standard certification processes

Typical usage ratio

• Generally utilized at ≥99.0% purity for preparation of parent standards; batch sizes typically 0.5–2% of commercial API synthesis lots depending on lab demand and storage capacity.

Downstream process integration

• Purified in small-scale synthesis reactors, crystallized or reconstituted before packaging as standardized solutions or powders for analytical method validation kits.

Final product types

• Certified steroid hormone reference standards
• Quality control and calibration samples for HPLC, GC-MS, and LC-MS

5. Progestin Intermediate for Contraceptive Device Manufacturing

Device manufacturers producing intrauterine and implantable contraceptive systems utilize 16A,17A-Epoxyprogesterone to synthesize progestin agents with precisely defined release characteristics. This precursor allows formulation labs to tailor hormone profiles meeting long-acting device requirements, with full GMP documentation and trace residual analysis throughout the polymer-drug fabrication process.

Industry compliance standards

• ISO 13485:2016 (Medical devices—Quality management systems)
• 21 CFR Part 820 (US FDA Quality System Regulation)
• EU MDR 2017/745 for medical devices
• Pharmaceutical composition monographs relevant to device APIs

Typical usage ratio

• Included at 10–18% (API-to-polymer mass), precisely controlled depending on device type and targeted hormone release profile.

Downstream process integration

• Employed in device API synthesis phase, then compounded with medical-grade polymers in extrusion or molding processes.

Final product types

• Polymer-based intrauterine systems (IUS) impregnated with progestins
• Subdermal contraceptive implants